Hims & Hers Stocks Plunge 15.37% as Margin Squeeze Forces EBITDA Guidance Cut
Hims & Hers Health (HIMS) shares fell 15.37% to $19.42 after Q3 results missed expectations. Revenue rose 49% to $890.4M, but gross margin dropped to 57% from 74%. The company cut its 2026 adjusted EBITDA guidance to $257M-$277M and revenue outlook to $3.13B-$3.15B, citing a marketing slowdown ahead of platform expansions.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut reflect operational challenges; investors may reprice the stock accordingly.
Market read
The fresh earnings and guidance update constitute primary market-moving news for HIMS, driving a significant intraday price drop.
What to watch
Potential upside from upcoming platform expansions and subscriber base growth if execution improves.
Background
Hims & Hers is a telehealth platform that has been expanding its subscriber base but faces margin pressure from high marketing spend.
Ticker impact
Hims & Hers reported Q3 results missing revenue and earnings and cut full-year adjusted EBITDA guidance, causing a 15.37% share plunge.
downward pressure as investors price in lower EBITDA and shrinking margins
The earnings miss and reduced guidance are fresh primary information; the stock already fell sharply, indicating market sensitivity.
Market effects
Telehealth and digital health peers may face heightened scrutiny on margin sustainability.
U.S. healthcare sector could see modest pullback as investors reassess growth assumptions.
Limited; impact confined to U.S. listed telehealth stocks.
Counterpoint
If the company successfully reins in marketing spend, margins could improve faster than expected, offering a buying opportunity at lower levels.
Key entities
- companyHims & Hers Health
NYSE-listed telehealth provider (ticker HIMS).
